Home » ANTITUSSIVE
Category Archives: ANTITUSSIVE
- Molecular FormulaC30H53NO11
- Average mass603.742 Da
104-31-4[RN]2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl 4-(butylamino)benzoateбензонататبنزوناتات苯佐那酯ベンゾナテート;KM 652,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate
Benzonatate bulk and Benzonatate capsules 100mg, cdsco india 2021, 15.07.2021
For the treatment of refractory coughCAS Registry Number: 104-31-4CAS Name: 4-(Butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl esterAdditional Names: nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; p-butylaminobenzoic acid w-O-methylnonaethyleneglycol ester; benzononatineTrademarks: Exangit; Tessalon (Forest)Molecular Formula: C30H53NO11Molecular Weight: 603.74Percent Composition: C 59.68%, H 8.85%, N 2.32%, O 29.15%Literature References: Prepn: Matter, US2714608 (1955 to Ciba).Properties: Colorless to faintly yellow oil. Soluble in most organic solvents except aliphatic hydrocarbons.Therap-Cat: Antitussive.Keywords: Antitussive.
Matter, M.; U.S. Patent 2,714,608; August 2, 1955; assigned to Ciba Pharmaceutical Products, Inc.
Substances Referenced in Synthesis Path
|CAS-RN||Formula||Chemical Name||CAS Index Name|
|94-32-6||C13H19NO2||ethyl 4-butylaminobenzoate||Benzoic acid, 4-(butylamino)-, ethyl ester|
|6048-68-6||C19H40O10||nonaethylene glycol monomethyl ether||2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-ol|
Benzonatate, sold under the brand name Tessalon among others, is a medication used to try to help with the symptoms of cough and hiccups. It is taken by mouth. Use is not recommended in those under the age of ten. Effects generally begin within 20 minutes and last up to eight hours.
Side effects include sleepiness, dizziness, headache, upset stomach, skin rash, hallucinations, and allergic reactions. Excessive doses may cause seizures, irregular heartbeat, and death. Chewing or sucking on the capsule can lead to laryngospasm, bronchospasm, and circulatory collapse. It is unclear if use in pregnancy or breastfeeding is safe. It works by numbing stretch receptors in the lungs and suppressing the cough reflex in the brain.
Benzonatate was approved for medical use in the United States in 1958. It is available as a generic medication. It is not available in many countries. In 2018, it was the 113th most commonly prescribed medication in the United States, with more than 6 million prescriptions.
100mg generic benzonatate capsules
Benzonatate is a prescription non-opioid alternative for the symptomatic relief of cough. It has been shown to improve cough associated with a variety of respiratory conditions including asthma, bronchitis, pneumonia, tuberculosis, pneumothorax, opiate-resistant cough in lung cancer, and emphysema.
Benzonatate does not treat the underlying cause of the cough.
Benzonatate has been shown to have use in the suppression of hiccups.
Benzonatate acts as a local anesthetic and the liquid inside the capsule can be applied in the mouth to numb the oropharynx for awake intubation. However, there can be life-threatening adverse effects when the medication is absorbed by the oral mucosa, including choking, hypersensitivity reactions, and circulatory collapse.
Hypersensitivity to benzonatate or any related compounds is a contraindication to its administration.
- Constipation, dizziness, fatigue, stuffy nose, nausea, headache are frequently reported.
- Sedation, a feeling of numbness in the chest, sensation of burning in the eyes, a vague “chilly” sensation, itchiness, and rashes are also possible.
- Ingestion of a small handful of capsules has caused seizures, cardiac arrhythmia, and death in adults.
Benzonatate is structurally related to anesthetic medications of the para-aminobenzoic acid (PABA) class which includes procaine and tetracaine. Procaine and tetracaine, previously used heavily in the fields of dentistry and anesthesiology, have fallen out of favor due to allergies associated with their metabolites. Similarly, severe hypersensitivity reactions to benzonatate have been reported and include symptoms of laryngospasm, bronchospasm, and cardiovascular collapse. These reactions are possibly associated with chewing, sucking, or crushing the capsule in the mouth.
Benzonatate should be swallowed whole. Crushing or sucking on the liquid-filled capsule, or “softgel,” will cause release of benzonatate from the capsule and can produce a temporary local anesthesia of the oral mucosa. Rapid development of numbness of the tongue and choking can occur. In severe cases, excessive absorption can lead to laryngospasm, bronchospasm, seizures, and circulatory collapse. This may be due to a hypersensitivity reaction to benzonatate or a systemic local anesthetic toxicity, both of which have similar symptoms. There is a potential for these adverse effects to occur at a therapeutic dose, that is, a single capsule, if chewed or sucked on in the mouth.
Isolated cases of bizarre behavior, mental confusion, and visual hallucinations have been reported during concurrent use with other prescribed medications. Central nervous system effects associated with other para-aminobenozic acid (PABA) derivative local anesthetics, for example procaine or tetracaine, could occur with benzonatate and should be considered.
Safety and efficacy in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below the age of 10. Benzonatate may be attractive to children due to its appearance, a round-shaped liquid-filled gelatin capsule, which looks like candy. Chewing or sucking of a single capsule can cause death of a small child. Signs and symptoms can occur rapidly after ingestion (within 15–20 minutes) and include restlessness, tremors, convulsions, coma, and cardiac arrest. Death has been reported within one hour of ingestion.
Pregnancy and breast feeding
In the U.S., benzonatate is classified by the U.S. Food and Drug Administration (FDA) as pregnancy category C. It is not known if benzonatate can cause fetal harm to a pregnant woman or if it can affect reproduction capacity. Animal reproductive studies have not yet been conducted with benzonatate to evaluate its teratogenicity. Benzonatate should only be given to a pregnant woman if it is clearly needed.
Benzonatate overdose is characterized by symptoms of restlessness, tremors, seizures, abnormal heart rhythms (cardiac arrhythmia), cerebral edema, absent breathing (apnea), fast heart beat (tachycardia), and in severe cases, coma and death. Symptoms develop rapidly, typically within 1 hour of ingestion. Treatment focuses on removal of gastric contents and on managing symptoms of sedation, convulsions, apnea, and cardiac arrhythmia.
Despite a long history of safe and appropriate usage, the safety margin of benzonatate is reportedly narrow. Toxicity above the therapeutic dose is relatively low and ingestion of a small handful of pills can cause symptoms of overdose. Children are at an increased risk for toxicity, which have occurred with administration of only one or two capsules.
Due to increasing usage of benzonatate and rapid onset of symptoms, there are accumulating cases of benzonatate overdose deaths, especially in children.
Mechanism of action
Similar to other local anesthetics, benzonatate is a potent voltage-gated sodium channel inhibitor. After absorption and circulation to the respiratory tract, benzonatate acts as a local anesthetic, decreasing the sensitivity of vagal afferent fibers and stretch receptors in the bronchi, alveoli, and pleura in the lower airway and lung. This dampens their activity and reduces the cough reflex. Benzonatate also has central antitussive activity on the cough center in central nervous system at the level of the medulla. However, there is minimal inhibition of the respiratory center at a therapeutic dosage.
Benzonatate is hydrolyzed by plasma butyrylcholinesterase (BChE) to the metabolite 4-(butylamino)benzoic acid (BABA) as well as polyethylene glycol monomethyl esters. Like many other local anesthetic esters, the hydrolysis of the parent compound is rapid. There are concerns that those with pseudocholinesterase deficiencies may have an increased sensitivity to benzonatate as this hydrolysis is impaired, leading to increased levels of circulating medication.
Benzonatate is a butylamine, structurally related to other polyglycol ester local anesthetics such as procaine and tetracaine. The molecular weight of benzonatate is 603.7 g/mol. However, the reference standard for benzonatate is a mixture of n-ethoxy compounds, differing in the abundance of 7-9 repeating units, with an average molecular weight of 612.23 g/mol. There is also evidence that the compound is not uniform between manufacturers.
Society and culture
Benzonatate was first made available in the U.S. in 1958 as a prescription medication for the treatment of cough in individuals over the age of 10. There are a variety of prescription opioid-based cough relievers, such as hydrocodone and codeine, but have unwanted side effects and potential of abuse and diversion. However, benzonatate is currently the only prescription non-opioid antitussive and its usage has been rapidly increasing. The exact reasons of this increase are unclear.
In the United States between 2004 and 2009, prescriptions increased 50% from 3.1 million to 4.7 million, the market share of benzonatate among antitussives increased from 6.3% to 13%, and the estimated number of children under the age of 10 years receiving benzonatate increased from 10,000 to 19,000. Throughout this same period, greater than 90% of prescriptions were given to those 18 or older. The majority of prescriptions were given by general, family, internal, and osteopathic physicians with pediatricians account for about 3% of prescribed benzonatate.
Tessalon is a brand name version of benzonatate manufactured by Pfizer, Inc. It is available as perles or capsules. Zonatuss was a brand name manufactured by Atley Pharmaceuticals, Inc. and Vertical Pharmaceuticals, Inc.
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s “Benzonatate Monograph for Professionals”. Drugs.com. American Society of Health-System Pharmacists. Retrieved 23 March 2019.
- ^ Jump up to:a b c Becker, DE (2010). “Nausea, vomiting, and hiccups: a review of mechanisms and treatment”. Anesthesia Progress. 57 (4): 150–6, quiz 157. doi:10.2344/0003-3006-57.4.150. PMC 3006663. PMID 21174569.
- ^ Jump up to:a b c d “Drugs for cough”. The Medical Letter on Drugs and Therapeutics. 60 (1562): 206–208. 17 December 2018. PMID 30625123.
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u v w x y z “Tessalon – benzonatate capsule”. DailyMed. 20 November 2019. Retrieved 21 April 2020.
- ^ Jump up to:a b c d e f “Benzonatate Use During Pregnancy”. Drugs.com. 10 October 2019. Retrieved 20 February 2020.
- ^ Walsh, T. Declan; Caraceni, Augusto T.; Fainsinger, Robin; Foley, Kathleen M.; Glare, Paul; Goh, Cynthia; Lloyd-Williams, Mari; Olarte, Juan Nunez; Radbruch, Lukas (2008). Palliative Medicine E-Book. Elsevier Health Sciences. p. 751. ISBN 9781437721942.
- ^ Jump up to:a b “The Top 300 of 2021”. ClinCalc. Retrieved 18 February2021.
- ^ Jump up to:a b “Benzonatate – Drug Usage Statistics”. ClinCalc. Retrieved 18 February 2021.
- ^ Jump up to:a b c d Homsi, J.; Walsh, D.; Nelson, K. A. (November 2001). “Important drugs for cough in advanced cancer”. Supportive Care in Cancer. 9 (8): 565–574. doi:10.1007/s005200100252. ISSN 0941-4355. PMID 11762966. S2CID 25881426.
- ^ Estfan, Bassam; LeGrand, Susan (November 2004). “Management of cough in advanced cancer”. The Journal of Supportive Oncology. 2 (6): 523–527. ISSN 1544-6794. PMID 16302303.
- ^ Jump up to:a b c d e f g h i j k l McLawhorn, Melinda W.; Goulding, Margie R.; Gill, Rajdeep K.; Michele, Theresa M. (January 2013). “Analysis of benzonatate overdoses among adults and children from 1969-2010 by the United States Food and Drug Administration”. Pharmacotherapy. 33 (1): 38–43. doi:10.1002/phar.1153. ISSN 1875-9114. PMID 23307543. S2CID 35165660.
- ^ Jump up to:a b “Benzonatate (Professional Patient Advice)”. Drugs.com. 4 March 2020. Retrieved 21 April 2020.
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u v w Bishop-Freeman SC, Shonsey EM, Friederich LW, Beuhler MC, Winecker RE (June 2017). “Benzonatate Toxicity: Nothing to Cough At”. J Anal Toxicol. 41 (5): 461–463. doi:10.1093/jat/bkx021. PMID 28334901.
- ^ Jump up to:a b “Drugs for Cough”. The Medical Letter on Drugs and Therapeutics. 60 (1562): 206–208. 17 December 2018. PMID 30625123.
- ^ Jump up to:a b c d e f “FDA Drug Safety Communication: Death resulting from overdose after accidental ingestion of Tessalon (benzonatate) by children under 10 years of age”. U.S. Food and Drug Administration (FDA). 28 June 2019. Retrieved 22 April 2020.
- ^ Jump up to:a b c “In brief: benzonatate warning”. The Medical Letter on Drugs and Therapeutics. 53 (1357): 9. 7 February 2011. ISSN 1523-2859. PMID 21304443.
- ^ “Tessalon- benzonatate capsule”. DailyMed. 20 November 2019. Retrieved 25 April 2020.
- ^ “Zonatuss (Benzonatate Capsules USP, 150 mg)”. DailyMed. 2 June 2010. Retrieved 20 August 2020.
- ^ “Zonatuss (Benzonatate Capsules USP, 150 mg)”. DailyMed. 31 October 2016. Retrieved 20 August 2020.
- “Benzonatate”. Drug Information Portal. U.S. National Library of Medicine.
|Trade names||Tessalon, Zonatuss, others|
|License data||US DailyMed: Benzonatate|
|ATC code||R05DB01 (WHO)|
|Legal status||US: ℞-only|
|Elimination half-life||3-8 hours|
|CompTox Dashboard (EPA)||DTXSID9022655|
|Chemical and physical data|
|Molar mass||603.750 g·mol−1|
|3D model (JSmol)||Interactive image|
|(what is this?) (verify)|
///////////Benzonatate, refractory cough , INDIA 2021, APPROVALS 2021, бензонатат , بنزوناتات , 苯佐那酯 , KM 65 , ベンゾナテート, ANTITUSSIVE, IND 2021
NEW DRUG APPROVALS